Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-04-23 AGM Information
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Förändringar i SynAct Pharmas valberedning inför årsstämman 2024
AGM Information Classification · 95% confidence The document is a press release announcing changes to the composition of the Nomination Committee (Valberedning) for the upcoming Annual General Meeting (AGM) of SynAct Pharma AB. It details which individuals are replacing others in the committee following decisions made at an Extraordinary General Meeting. This type of announcement, concerning the composition of the board/management structure or related preparatory bodies for the AGM, falls under Board/Management Information (MANG) or potentially Governance Information (CGR). Since it specifically details changes in representatives for the nomination committee, which is closely tied to board composition and governance leading up to the AGM, MANG is the most appropriate fit as it covers changes in senior company structure/representation. It is not a full AGM presentation (AGM-R), a proxy statement (PSI), or a general regulatory filing (RNS), as the content is highly specific to management/governance structure changes.
2024-04-23 Swedish
Kallelse till extra bolagsstämma i SynAct Pharma AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till extra bolagsstämma i SynAct Pharma AB" (Notice of Extraordinary General Meeting in SynAct Pharma AB). It details the date, time, location, registration requirements, and the proposed agenda for an extraordinary general meeting (EGM). The agenda items explicitly include proposals for approving directed share issues (nyemission) to investors, board members, and management. A notice for a general meeting, especially one detailing voting items like share issues, falls under the category of materials related to shareholder meetings. Since it is a notice calling for an EGM and outlines the proposals to be voted upon, it is most closely related to the materials distributed to shareholders for voting purposes, which aligns best with Proxy Solicitation & Information Statement (PSI) or potentially AGM-R if it were the Annual General Meeting. Given it is an *Extra* General Meeting (EGM) notice detailing proposals, PSI is a strong fit, but the core purpose is calling the meeting itself. However, the content is a formal notice calling a meeting where specific corporate actions (share issues) requiring shareholder approval are proposed. This structure is typical of a notice preceding a shareholder vote. Since the definitions include AGM-R for AGM materials, and this is an EGM notice, the closest fit among the options that cover shareholder meetings and associated materials is AGM-R (interpreted broadly for General Meeting materials) or PSI. Given the document is the formal 'Kallelse' (Notice) and details the voting items, it functions as the primary solicitation document for that meeting. Let's re-evaluate the options: AGM-R is for AGM materials. PSI is for Proxy Solicitation & Information Statement. Since this is a notice for an *Extra* General Meeting (EGM) detailing the agenda and proposals, it serves the function of informing shareholders and soliciting their participation/vote. PSI is often used for proxy materials sent out before a meeting. Given the explicit call to attend and the detailed agenda items requiring shareholder approval, PSI is a very strong candidate, as it solicits votes on specific proposals. However, if we consider the Swedish context where these notices are formal regulatory announcements, and given the focus on the meeting itself, AGM-R (interpreted as General Meeting materials) or RNS (as a general regulatory announcement) could apply. Since the document is the formal notice calling the meeting and detailing the voting items, it is fundamentally a proxy/meeting document. I will classify it as PSI because it solicits shareholder action (voting) on specific proposals, which is the core function of proxy materials, even though it is the initial notice rather than the full proxy statement itself. If PSI is too narrow, RNS is the fallback. Let's check the definitions again. AGM-R is for presentations/materials *shared during* the AGM. This is the *notice* calling the EGM. PSI covers materials sent to shareholders to provide information and request votes. This fits perfectly. I will assign PSI.
2024-03-27 Swedish
Notice of extraordinary general meeting in SynAct Pharma AB
AGM Information Classification · 99% confidence The document is titled "Notice of extraordinary general meeting in SynAct Pharma AB" and details the date, time, and location for the meeting. It outlines the procedures for shareholders to attend, including registration deadlines and proxy rules. Crucially, the proposed agenda items (Items 8, 9, and 10) concern resolutions for the approval of directed issues of new shares to investors, board members, and management. This content—a formal notice convening a shareholder meeting and detailing the proposals to be voted upon—is characteristic of materials prepared for a General Meeting. Since the document is the notice/material for the meeting itself, and not the subsequent voting results (DVA) or a general proxy solicitation (PSI), the most appropriate classification is AGM-R (AGM Information), as an extraordinary general meeting (EGM) falls under this umbrella of meeting materials.
2024-03-27 English
SynAct Pharma AB har framgångsrikt avslutat bookbuilding-förfarandet – riktade nyemissioner tillför bolaget totalt upp till 49,2 MSEK
Share Issue/Capital Change Classification · 98% confidence The document is a press release detailing the successful completion of a bookbuilding process for directed new share issues (Riktade Nyemissioner) intended to raise capital (up to 49.2 MSEK). It explicitly discusses the terms of the share issuance, the subscription price (8.60 SEK), the rationale for bypassing shareholder pre-emption rights, and the need for subsequent approval by an Extraordinary General Meeting (EGM). This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves share issuance (SHA), the primary focus and context is the financing activity itself.
2024-03-27 Swedish
SynAct Pharma AB has successfully completed the bookbuilding procedure - directed issues provide the company with a total of up to 49.2 MSEK.
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the successful completion of a bookbuilding procedure resulting in directed issues of new shares to raise capital (up to 49.2 MSEK). It details three directed issues (Directed Issue 1, 2, and 3) involving existing owners, board members, and management. The core subject is the issuance of new shares and the associated capital structure change, which is explicitly covered by the 'Capital/Financing Update' definition. Although it involves share issuance, the primary focus is the financing event and the capital raised, making 'CAP' the most appropriate classification over 'SHA' (which is typically for splits or general share changes without this context of immediate fundraising). The document also mentions convening an extraordinary general meeting to approve the issues, but it is not the proxy statement (PSI) or the voting results (DVA).
2024-03-27 English
SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release titled "SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK". It details plans for raising capital through new share issues (Directed Issue 1, 2, and 3), deviation from preferential rights, and the use of an accelerated bookbuilding procedure. This content directly relates to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves share issues, the primary focus is the financing activity itself, rather than just a simple share repurchase (POS) or a general regulatory announcement (RNS). It is not a full financial report (10-K, IR) or a simple dividend notice (DIV).
2024-03-26 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.